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Abstract
JC virus (JCV) is a common human polyomavirus that infects 70–80% of the population worldwide. In immunosuppressed individuals,
JCV infects oligodendrocytes and causes a fatal demyelinating disease known as progressive multifocal leukoencephalopathy (PML). The
tropism of JCV is restricted to oligodendrocytes, astrocytes, and B lymphocytes. Several mechanisms may contribute to the restricted
tropism of JCV, including the presence or absence of cell-type-specific transcription and replication factors and the presence or absence of
cell-type-specific receptors. We have established a system to investigate cellular factors that influence viral tropism by selecting
JCV-resistant cells from a susceptible glial cell line (SVG-A). SVG-A cells were subjected to several rounds of viral infection using JC virus
(M1/SVE). A population of resistant cells emerged (SVGR2) that were refractory to infection with the Mad-4 strain of JCV, the hybrid
virus M1/SVE, as well as to the related polyomavirus SV40. SVGR2 cells were as susceptible as the SVG-A cells to infection with an
unrelated amphotropic retrovirus. The stage at which these cells are resistant to infection was investigated and the block appears to be at
early viral gene transcription. This system should ultimately allow us to identify glial specific factors that influence the tropism of JCV.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
JC virus is the causative agent of the fatal central nervous
system (CNS) demyelinating disease progressive multifocal
leukoencephalopathy (PML) that is due to JCV-induced
lytic destruction of myelin-producing oligodendrocytes
within the CNS. Although roughly 70–80% of the world-
wide population has been exposed to JCV, disease occurs
only in immunocompromised individuals and approxi-
mately 4–6% of AIDS patients develop PML (Hou and
Major, 2000). It is thought that immunosuppression can
allow reactivation of latent virus which can spread to the
CNS and infect oligodendrocytes (Lipton, 1991; Major et
al., 1992; Telenti et al., 1992; Tornatore et al., 1994), and
some have suggested that reactivation of latent virus within
the CNS can contribute to the development of PML (Elsner
and Dorries, 1992; Mori et al., 1991; Vago et al., 1996;
White et al., 1992).
JCV is a nonenveloped polyomavirus with double-
stranded, circular DNA. The viral life cycle is temporally
regulated with early gene expression occurring after the
genome invades the nucleus of a cell. Early gene expression
is followed by replication of the DNA and late gene expres-
sion. JCV is efficiently replicated only in glial cells. The
reason for this restricted tropism is not understood, but may
be due to the presence of cell-type-specific factors such as a
receptor or transcription factors. Infection of glial cells has
been shown to be dependent on the presence of an N-linked
glycoprotein containing (2–6)-linked sialic acid and its
removal results in the amelioration of infection (Liu, Wei,
and Atwood, 1998). JCV virus-like particles (VLP) have
been shown to bind other oligosacharrides (Komagome et
al., 2002) and, although viral binding seems to correlate
with susceptibility in primary cells (Wei, Liu, and Atwood,
2000), the relationship between viral binding and cellular
susceptibility is complicated by the many cell lines that bind
virus but lack the ability to support infection (Suzuki et al.,
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2001). These data indicate that the presence of the correct
receptor is not enough to render a cell permissive to JCV
infection. The JCV promoter has been shown to be more
active in glial cells than in cells of other lineages (Feigen-
baum, Hinrichs, and Jay, 1992; Kenney et al., 1984; Raj and
Khalili, 1995), but this has not been proven to establish
susceptibility. Active JC viral replication can be detected in
oligodendrocytes, astrocytes, and B lymphocytes (Atwood
et al., 1992; Major et al., 1992; Major et al., 1985; Sweet
and Valle, 2002) but JCV DNA and early protein expression
can be detected in a wider variety of cell types (Bendiksen
et al., 2000; Dubois et al., 1997; Monaco et al., 1996;
Ricciardiello et al., 2000), suggesting that multiple factors
are responsible for the tropism of the virus.
Despite significant progress in understanding transcrip-
tional control of the JCV promoter in glial cells a glial
specific factor that determines virus tropism has remained
elusive (Chen and Khalili, 1995; Kerr et al., 1994; Lassak et
al., 2002; Monaco et al., 2001; Raj et al., 1996; Ranga-
nathan and Khalili, 1993). This may be due to the lack of an
efficient model for studying JCV tropism combined with the
possibility that multiple factors are likely to be involved.
We have established a system to investigate cellular factors
that influence viral tropism by selecting JCV-resistant cells
from a susceptible glial cell line (SVG-A). We infected
SVG-A cells with JCV and established the resistant SVGR2
cell line by propagating cells that survived multiple rounds
of lytic infection. The SVGR2 cell line proved to be resis-
tant to infection by the Mad-4 strain of JCV, a chimeric JCV
virus that contains elements of the SV40 promoter/enhancer
region (M1/SVE) (Vacante, Traub, and Major, 1989), as
well as to SV40. The resistant cells were, however, as
susceptible as the parental cell line to infection by an un-
related retrovirus. We determined that the block to infection
in SVGR2 cells is at the transcriptional level as the cells are
also resistant to infection by viral DNA. Furthermore, both
JCV and SV40 early promoter activity is significantly re-
duced in SVGR2 cells compared to SVG-A cells. The tran-
scriptional block is specific for JCV and SV40 promoters as
the cytomegalovirus (CMV) early promoter is unaffected.
In addition the cells are susceptible to infection by an
unrelated retrovirus. This novel cell line should allow us to
establish which glial specific factors directly control JCV
transcriptional activity.Fig. 1. SVGR2 cells are resistant to infection by multiple polyomaviruses.
Staining for late viral proteins three days postinfection with JCV reveals
that viral protein expression is undetectable in noninfected cells (A and B)
and that, compared to SVG-A cells (A, C, E, G, and I), SVGR2 cells (B,
D, F, H, and J) are resistant to the chimeric virus M1/SVE (C and D),
Mad-4 JCV (E and F) and the related polyomavirus, SV40 (G and H). An
unrelated, amphotropic retrovirus carrying the enhanced green fluorescent
protein (EGFP) gene driven by the Moloney murine leukemia virus (Mo-
MuLV) 5 LTR was used to show that the block to infection in SVGR2 cells
is specific for JCV and SV40 infection (I and J). Comparable expression of
EGFP after infection indicates that the control virus is equally infectious in
both cell types.
Fig. 2. SVG-A and SVGR2 cells express glial fibrillary acidic protein
(GFAP). GFAP is the protein that composes intermediate filaments in
astrocytes. GFAP expression was detected with a mouse monoclonal an-
tibody specific for human GFAP and Alexafluor 488-conjugated goat
antimouse secondary antibody. Nuclei were visualized by mounting cov-
erslips in medium with propdium iodide. (A and C) SVG-A and SVGR2
cells stained without primary antibody; (B and D) equal expression of
GFAP in SVG-A and SVGR2 cells.
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Results
SVGR2 cells are resistant to infection by JCV and SV40
To determine whether SVGR2 cells that survived multi-
ple rounds of lytic infection with the M1/SVE virus were
resistant to infection, we challenged them with both M1/
SVE and the Mad-4 strain of JCV. To assay for suscep-
tibility to the virus, we used indirect immunofluorescence
microscopy at three days postinfection to stain for the late
viral protein V-antigen. Less than 1% of the surviving
SVGR2 cells were susceptible to infection (Fig. 1C–F). We
also infected the cells with SV40 and found that infection
was also significantly reduced in SVGR2 cells (Fig. 1G and
H). Since the M1/SVE virus used to derive the SVGR2
cells contains elements of the SV40 genome in its promoter,
it is likely that we derived a cell line that is resistant to both
viruses.
We next asked whether this resistance was specific to
JCV and SV40 or if our approach had created a cell line that
was nonspecifically resistant to viral infection. To investi-
gate this, we used an unrelated, amphotropic retrovirus
carrying the enhanced green fluorescent protein (EGFP)
Fig. 3. FITC-labeled virus binding on SVG-A and SVGR2 cells. In order
to investigate whether SVGR2 cells were resistant to JCV at the level of
virus binding, we compared the level of virus binding of the resistant cells
to the susceptible parental cell line. FITC-labeled M1/SVE virus was
added to each cell type and the level of virus binding was determined by
mean fluorescence intensity (MFI) using flow cytometry. Shaded area
represents cells without added virus, the thin line represents SVG-A cells
incubated with virus and the thick line represents SVGR2 cells with labeled
virus. The MFI, representing the amount of FITC-labeled virus that binds
to SVGR2, cells is not reduced compared to SVG-A cells.
Fig. 4. (A) JCV protein expression is blocked in SVGR2 cells at a point following viral entry. To investigate whether SVGR2 cells could support viral protein
expression, we introduced viral DNA into the cells by transfection. Three days later, cells were fixed and V-antigen was detected by indirect immunoflu-
orescence. Viral proteins are expressed at high levels in SVG-A cells transfected with viral DNA (panel b) but at low levels in SVGR2 cells transfected with
viral DNA (panel d). (B) Infected cells were counted and numbers were normalized for transfection efficiency. Even when the normal virus–receptor
interaction was bypassed, JCV protein production was significantly reduced in SVGR2 cells.
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gene driven by the Moloney murine leukemia virus (Mo-
MuLV) 5 LTR. We infected SVG-A and SVGR2 cells with
this retrovirus and identified infected cells by EGFP expres-
sion. SVG-A and SVGR2 cells proved to be equally suscep-
tible to infection by this virus (Fig. 1I and J), indicating that the
block to infection in SVGR2 cells is specific for JCV and
SV40.
To ensure that we had not selected a subpopulation of
nonglial cells from the original SVG-A glial cell line we
stained both cell types with an antibody to the astrocyte
specific marker glial fibrillary acidic protein (GFAP). Both
SVG-A and SVGR2 cells expressed GFAP (Fig. 2B and D),
consistent with their astroglial lineage (Major et al., 1985).
Viral binding is not reduced in SVGR2 cells
The cellular receptor for JCV is currently unknown, but
it is thought to be an N-linked glycoprotein containing
(2–6)-linked sialic acids (Liu, Wei, and Atwood, 1998).
We reasoned that SVGR2 cells would be resistant to infec-
tion if they lacked a functional form of this receptor. Be-
cause we were unable to screen for the presence of the
receptor directly, we compared the levels of virus binding
between the resistant cells and the susceptible parental cell
line. FITC-labeled M1/SVE was diluted in PBS and added
to SVG-A and SVGR2 cells. The level of virus binding was
determined by mean fluorescence intensity (MFI) using
flow cytometry. The MFI of untreated SVG-A cells was
used as a control and all samples were gated on live cells.
The level of virus binding to each cell type was equivalent
(Fig. 3). Because there was no significant difference in virus
binding between the cell types, we concluded that the block
to infection of SVGR2 cells occurs after the initial virus–
cell interaction.
SVGR2 cells are resistant to infection by viral DNA
To investigate whether SVGR2 cells were resistant to
infection with viral DNA we transfected both SVG-A and
SVGR2 cells with DNA isolated from M1/SVE virions.
V-antigen (V Ag) expression was then scored at 3 days
posttransfection by indirect immunofluorescence micros-
copy. SVGR2 cells remained refractory to infection with
viral DNA indicating that the block to infection was down-
stream of receptor binding and entry (Fig. 4A, panels b and
d). A cytomegalovirus (CMV)-gal reporter plasmid was
used to control for transfection efficiency. At 48 h posttrans-
fection -galactosidase-expressing cells were scored by
counting blue cells. -Galactosidase expression was slightly
reduced in SVGR2 cells compared to SVG-A cells. To
ensure that this reduced expression of the reporter gene was
not due to a defect in CMV promoter activity, the transfec-
tion efficiencies of both cell lines were confirmed using a
Southern blot to compare levels of transfected DNA (data
not shown). We found the transfection efficiency of SVGR2
to be reduced approximately 2.5-fold compared to SVG-A
cells using both methods. We then used this number to
normalize for transfection efficiencies and found that
SVGR2 cells were still resistant to infection by JCV DNA
compared to SVG-A cells (Fig. 3B).
To further show that the block to infection of SVGR2
cells was transcriptional we used a chloramphenicol acetyl-
transferase (CAT) reporter gene assay. SVG-A and SVGR2
cells were transfected with pM1CAT and pSV2CAT DNA.
The pM1CAT reporter construct produces chloramphenicol
acetyltransferase under the control of the Mad-1 JCV early
promoter as previously described (Atwood et al., 1995). The
pSV2CAT reporter construct is driven by the SV40 early
promoter. The activity of each promoter was determined by
harvesting equal amounts of protein from the cells and
testing for CAT activity over time. Transfection efficiencies
were controlled for with the CMV-gal assay. The activity
of pM1CAT was reduced 2.3-fold and pSV2CAT activity
was reduced 7.7-fold (Fig. 5). Taken together, these data
clearly show that there is a defect in JCV and SV40 viral
transcription that does not extend to CMV or retroviral gene
transcription.
Although promoter activity was reduced in SVGR2 cells,
Fig. 5. CAT assays show that activity of both the Mad-1 early JCV promoter and the SV40 early promoter is reduced in SVGR2 cells compared to SVG-A
cells. In SVGR2 cells, Mad-1 promoter activity (measured with pM1CAT) was reduced 2.3-fold and SV40 promoter activity (measured with pSV2CAT) was
reduced 7.7-fold compared to SVG-A cells. Results were normalized for transfection efficiencies as before. Error bars represent the standard deviations from
three independent experiments.
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the transfection experiments indicated that SVGR2 cells did
support a small amount of basal promoter activity. We con-
sidered the possibility that this low level of activity could be
enough to allow viral transcription to occur and that there
might be a complete block to translation. In order to determine
if this were the case, we infected the SVG-A and SVGR2 cell
lines with M1/SVE. At 2 and 3 days postinfection, we har-
vested RNA from these cells and reverse transcribed it into
cDNA. We then used either JCV T-antigen- or V-antigen-
specific primers to amplify the early and late viral gene tran-
scripts. Early viral gene transcription was undetectable in
SVGR2 cells (Fig. 6A, lane 5) at polymerase chain reaction
(PCR) conditions that were sufficient to reveal transcription in
the parental cell line (Fig. 6A, lane 1). The late viral transcript
was also undetectable in infected SVGR2 cells (Fig. 6B, lane
7), whereas it was easily detected by PCR in the susceptible
SVG-A cell line (Fig. 6B, lane 5). To confirm that each reac-
tion contained the same amount of starting material, we per-
formed control experiments using GAPDH specific primers.
To ensure that we were not amplifying input viral DNA, we set
up reactions lacking reverse transcriptase as negative controls.
The fact that viral transcripts were not made in resistant,
infected cells led us to surmise that the block to infection must
occur prior to this step in the viral life cycle. Our data indicate
that the SVGR2 cell line is resistant to JCV infection due to a
deficit in viral gene transcription, not translation.
Resistant cells do not harbor latent virus
We next investigated whether our method of using JCV
to select for resistant cells had caused the cells to become
doubly transformed. Since there have been cases where a
preexisting viral infection prevents subsequent infection by
other viruses through various mechanisms of viral interfer-
ence (Potash and Volsky, 1998; VandeWoude et al., 2002),
we wanted to ensure that a second transformation event by
JCV T-Ag was not preventing the SVGR2 cells from be-
coming infected. To investigate whether SVGR2 cells har-
bored a latent JCV genome, PCR was carried out using JCV
T-antigen-specific primers on SVG-A and SVGR2 cells, as
well as three subclones of each (Fig. 7). The positive control
reaction was performed on 10 pg of JCV DNA. Uninfected
SVG-A cells were negative because the primers do not
cross-react with the SV40 T Ag used to initially transform
the SVG-A cell line. Low levels of JCV T-antigen DNA
were detected in the SVGR2 genome. This may be caused
by the presence of residual surviving cells that are suscep-
tible to JCV, or alternately, the resistance of some of the
cells could have been due to their transformation by JCV
T-Ag. We assumed that this was due to the fact that the
SVGR2 cell line was created from a pool of resistant cells.
This ambiguity was eliminated after the cells were sub-
cloned. All three subclones derived from SVGR2 cells were
entirely resistant to infection and were completely devoid of
JCV DNA, indicating that they are not latently infected with
the virus. This suggests that the cells are indeed resistant to
infection and that it is not merely superinfection or double
transformation that prevents JCV gene expression.
Discussion
The SVGR2 cell line was derived directly from the
JCV-sensitive SVG-A cell line and is resistant to infection
by JCV and SV40. SVGR2 cells are not, however, resistant
to infection by all viruses as revealed by infection with an
Fig. 6. RT–PCR experiments show that viral genes are not transcribed in
SVGR2 cells. RNA was isolated from cells that were uninfected or infected
using M1/SVE. After reverse transcription, (A) T-antigen or (B) V-
antigen specific primers were used to amplify JCV transcripts. GAPDH-
specific primers were used as a positive control and reverse transcriptase
was omitted as a negative control. (A) SVG-A cells infected with and
without reverse transcriptase (RT) (lanes 1 and 2), SVG-A uninfected cells
with and without RT (lanes 3 and 4), SVGR2 infected with and without RT
(lanes 5 and 6), SVGR2 uninfected with and without RT (lanes 7 and 8),
and no-template negative controls with and without RT (lanes 9 and 10).
(B) SVG-A uninfected with and without RT (lanes 1 and 2), SVGR2
uninfected with and without RT (lanes 3 and 4), SVG-A infected with and
without (RT) (lanes 5 and 6), and SVGR2 infected with and without RT
(lanes 7 and 8). Viral transcription was undetectable after SVGR2 cells
were infected with M1/SVE, indicating that these cells are resistant to the
virus at a point after viral binding, but prior to early viral gene transcrip-
tion.
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EGFP-expressing retrovirus. Equal expression of the astro-
cyte intermediate filament marker GFAP in both cell lines
indicates that SVGR2 cells still retain astroglial character-
istics. These data suggest that the SVGR2 cell line is dif-
ferent from the parental line in a way that is crucial to the
life cycle of JC virus. We attempted to characterize this
difference by comparing viral binding, infection, and viral
gene expression between the two cell lines. We have shown
that SVGR2 cells are resistant to infection by the Mad-4
strain of JCV, a chimeric JC/SV40 virus, and SV40 but are
permissive for the unrelated EGFP-expressing retrovirus.
Furthermore, we have directly shown that viral transcription
from the JCV and SV40 early promoters is reduced in
SVGR2 cells, although transcription from another DNA
viral promoter (CMV) is not reduced. The results of our
experiments suggest that SVGR2 cells are resistant to JCV
because they do not support the generation of viral tran-
scripts. As SVGR2 cells were derived from a virus contain-
ing portions of both the SV40 and JCV promoters, and they
are resistant to both JCV and SV40, it is likely that this
resistance is due to a block at viral transcription.
This approach has allowed us to derive a cell line that is
resistant to infection by a virus that is tropic for the parental
cell line. The fact that these two cell lines are closely related,
yet differ in their susceptibility to viral infection, suggests that
the adaptation that occurred in the resistant cell line must be
directly influencing infection. One possibility is that we elim-
inated a population of cells that was susceptible to JCV infec-
tion and the surviving cells consist of a subpopulation that was
naturally resistant. The similarities between the cell lines will
prove crucial in the search of the reason for the resistance to
infection of the derived cell line. Techniques such as cDNA
array analysis and subtractive hybridization rely on the ability
to discern between random variation and biologically impor-
tant differences. Library screening should also be simplified
since it is more likely that there is only a single factor different
between the two cell lines responsible for the resistance to
infection. The results of these screens will inevitably prove
more useful if the stage of viral resistance is determined prior
to screening for differences.
One cellular factor that has been shown to limit viral tro-
pism is the restricted expression of a specific receptor that
allows viral entry (Bai, Harfe, and Freimuth, 1993; Dalgliesh et
al., 1984; Haun et al., 1993; Haywood, 1994). Others have
shown that presence of a viral receptor may not be sufficient to
guarantee productive infection (Atwood and Norkin, 1989;
Bass and Greenberg, 1992; Mei and Wadell, 1995). Many
other host factors interact with the viral regulatory proteins
during the life cycle, and the neurotropism of JCV has been
attributed to its early promoter (Raj and Khalili, 1995). Al-
though no factors required for JCV infection have yet been
shown to be glial specific, the expression of some necessary
transcription factors are upregulated in the brain. Sequence
analysis has implicated that the different classes of nuclear
factor-1 (NF-1) interact with the JCV promoter (Tamura et al.,
1988). NF-1 class D has been shown to be upregulated in the
brain compared to the other classes (Sumner et al., 1996), and
recently it has been shown to play a role in JC virus multipli-
cation (Monaco et al., 2001). Since it is expressed in many
different cell types, it is likely that this factor is only partially
responsible for the tropism of the virus. It is also likely that the
regulatory region sequences of JCV limit viral expression to
certain cell types (Daniel et al., 1996; Liu et al., 1997), and
different arrangements within this region may influence the
tropism of JCV. For these reasons, the combinations of tran-
scription factors and negative regulatory factors that are
present within a cell may be the most important determinants
in the tropism of JCV.
This approach will allow us to compare a susceptible
glial cell to a resistant glial cell and should allow us to
elucidate a glial specific factor that determines JCV tropism.
Another benefit is that this approach can be used repeatedly
to study different aspects of the same virus. It should be
possible to derive several cell lines that are resistant for
different reasons using this system. These resistant lines
should provide models to ascertain different factors that are
involved in the viral life cycle. These data could then be
compiled to provide an understanding of the underlying
factors behind JCV tropism. It may also give insight into the
mechanism that allows disease to occur in only a small
fraction of infected individuals.
Materials and methods
Cells and virus
The SVG-A cell line was subcloned from the original
SVG cell line established by transformation of human fetal
glial cells by an origin-defective SV40 mutant (Major et al.,
Fig 7. Detection of JCV DNA sequences in SVGR2 cells. DNA extracted
from SVG-A cells (lane 2), SVG-A subclones (lanes 3–5), SVGR2 cells
(lane 6), and SVGR2 subclones (lanes 7–9) was analyzed for the presence
of JCV T-antigen sequences by PCR using primers specific for JCV
T-antigen. A positive control PCR reaction using JCV DNA was performed
under the same conditions (lane 1). JCV T-antigen transcript was not
detected in any subclones.
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1985). The SVGR2 cell line was derived from SVG-A cells
that survived multiple rounds of infection with the M1/
SVE virus. Several subclones were established from each
cell line by limited-dilution cloning. The cells were main-
tained in humidified 37°C CO2 incubators in Eagle’s min-
imum essential medium (EMEM) supplemented with 10%
heat-inactivated fetal bovine serum and antibiotics. The
laboratory strain of virus used was M1/SVE and the wild-
type strains used were JCV (Mad-4) and SV40 (776).
Indirect immunofluorescent assays
Cells grown on coverslips were infected for 1 h with
Mad-4 or M1/SVE JCV at a multiplicity of infection
(MOI) of 8.7  104 or with SV40 at a MOI of 45 in the
presence of EMEM plus 2% serum in a total volume of 100
l. At 3 days postinfection, coverslips were washed in PBS
and fixed for 10 min in acetone. The cells were incubated
with either the anti-V-antigen monoclonal antibody
PAB597 (undiluted hybridoma supernatant) or anti-T-anti-
gen antibody diluted 1:100 in PBS for 45 min at 37°C. Cells
were then washed three times with PBS and incubated with
a FITC-labeled goat antimouse secondary antibody for 45
min at 37°C. Cells were again washed three times with PBS,
counterstained with PBS containing 0.02% Evans blue, and
washed again in PBS. Coverslips were mounted on slides
and visualized on a Zeiss epifluorescence microscope and
images were captured by a digital camera.
GFAP expression was detected in acetone fixed cells
grown on glass coverslips using a mouse monoclonal anti-
body against human GFAP (Sigma) to detect the astrocyte-
specific intermediate filament protein. A goat antimouse
Alexaflour 488 secondary antibody was used to visualize
the protein. Nuclei were visualized with a propidium iodine
based mounting medium (Vector).
Transfection efficiency
SVG-A and SVGR2 cells were transfected with 1 g
plasmid DNA containing the -galactosidase gene driven
by the cytomegalovirus (CMV) promoter (pCMV-gal) by
standard CaPO4 transfection methods. Transfection effi-
ciency was determined using a -galactosidase reporter
gene staining kit (Sigma) to calculate a normalization factor
for further studies.
CAT assay
The CAT reporter plasmids pSV2CAT and pM1CAT
were introduced into each cell line by CaPO4-mediated
transfection. Each experiment was done in triplicate and
control experiments were also done with no DNA. Forty-
eight hours after transfection, cells were washed two times
in PBS, harvested by scraping, and lysed by three succes-
sive freeze–thaw cycles. Cell debris was removed by cen-
trifugation and the protein concentration of the cell extract
was determined by the Bradford method (Bradford, 1976).
Equivalent amounts of protein were assayed for CAT ac-
tivity with the fluor diffusion method described by Neuman
(Neuman, Morency, and Russian, 1987) and recorded over
3 h with a Beckman -counter.
Infection with retrovirus
Packaging cells were transfected with plasmid DNA car-
rying the enhanced green fluorescent protein (EGFP) gene
overnight in media containing 25 M chloroquine using
standard CaPO4 transfection techniques. Medium contain-
ing 25 M chloroquine was removed and replaced with
DMEM 16 h after it was added. Supernatant containing
amphotropic retrovirus was harvested at 72 h posttransfec-
tion. The retrovirus was purified by centrifugation or filtra-
tion and used immediately or, alternately, frozen at 80°C.
SVG-A and SVGR2 cells were transduced with retrovirus
diluted 50% with EMEM in the presence of 2 g/ml poly-
brene for 5 h.
Virus binding assays
For virus binding assays, cells were removed from tissue
culture dishes by incubation with Versene and resuspended
in PBS at 105 cells/ml. The cells were incubated on ice
either with increasing concentrations of FITC-labeled JCV
virions or without virus as a negative control. After a 30-
min incubation, cells were washed once in PBS containing
0.05 mg of propidium iodide/ml, washed twice in PBS, and
resuspended in PBS. The cells were immediately analyzed
on a Beckton–Dickenson FACScalibur flow cytometer.
Data gated on live cells was gathered using CellQuest™
software.
PCR and RT–PCR
For JCV T-antigen detection, DNA was isolated from
SVG-A and SVGR2 cells, as well as from three subclones
of each cell line, using standard phenol/chloroform extrac-
tion. The JCV T-antigen-specific primer sequences were
5-GAATAGGGGAGGAATCCATGG-3 and 5-GGAAT-
GCATGCAGATCTACAGG-3. Amplification was carried
out on 500 ng of template DNA in a total volume of 20 l.
The PCR program comprised of 35 cycles of denaturation at
95°C for 30 s, annealing at 60°C for 30 s, and extension at
72°C for 2 min. Samples amplified from JCV DNA served
as a positive control. Bands were visualized by separation of
samples on a 1% TAE agarose gel and visualized by stain-
ing with ethidium bromide.
For RT–PCR, total RNA was harvested from SVG-A and
SVGR2 cells 3 days postinfection with M1/SVE JCV at an
MOI of 8.7  104 using the S.N.A.P. Total RNA Isolation
kit (Invitrogen). Reverse transcription was performed for
T-antigen and V-antigen on 500 ng of total RNA using the
Access RT–PCR system (Promega) according to the man-
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ufacturer’s instructions. The primers were JCV V-antigen
specific: (upstream) JCV1991-2020 5-GCCACAGTG-
CAATCTCAAGTCATGAACACA-3 and (downstream)
JCV 2139-2121 5-GGAACATTTTCTCCTCCTG-3. The
PCR reaction was carried out for 30 cycles with a denatur-
ing step of 94°C for 30 s, annealing at 60°C for 60 s, and an
elongation step at 68°C for 2 min. This was followed by a
7-min final elongation step at 68°C. Samples were separated
on a 5% polyacrylamide gel and visualized by ethidium
bromide staining under UV light. A positive control reac-
tion was performed using glyceraldehyde-3-phosphate de-
hydrogenase- (GAPDH) specific primers and negative con-
trol reactions were carried out without reverse transcriptase.
Acknowledgments
We would like to thank all members of the Atwood
Laboratory for critical discussion during the course of this
work. We thank Dr. Eugene Major for the hybrid virus,
Mad-1, SVE, and for the original SVG cell line. Work in
our laboratory was supported by a grant from the National
Cancer Institute, R01 CA71878, and by grants from the
National Institutes of Health, R01 NS43097, P20 RR15578,
and P30-AI42853.
References
Atwood, W.J., Amemiya, K., Traub, R., Harms, J., Major, E.O., 1992.
Interaction of the human polyomavirus, JCV, with human B-lympho-
cytes. Virology 190, 716–723.
Atwood, W.J., Norkin, L.C., 1989. Class I major histocompatibility pro-
teins as cell surface receptors for simian virus 40. J. Virol. 63, 4474–
4477.
Atwood, W.J., Wang, L., Durham, L.C., Amemiya, K., Traub, R.G., Major,
E.O., 1995. Evaluation of the role of cytokine activation in the multi-
plication of JC virus (JCV) in human fetal glial cells. J. Neurovirol. 1,
40–49.
Bai, M., Harfe, B., Freimuth, P., 1993. Mutations that alter an Arg-Gly-Asp
(RGD) sequence in the adenovirus type 2 penton base protein abolish
its cell rounding activity and delay virus reproduction in flat cells.
J. Virol. 67, 5198–5205.
Bass, D.M., Greenberg, H.B., 1992. Strategies for the identification of
icosahedral virus receptors. J. Clin. Invest. 89, 3–9.
Bendiksen, S., Rekvig, O.P., VanGhelue, M., Moens, U., 2000. VP1 DNA
sequences of JC and BK viruses detected in urine of systemic lupus
erythematosus patients reveal no differences from strains expressed in
normal individuals. J. Gen. Virol. 81 (11), 2625–2633.
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal. Biochem. 72, 248–254.
Chen, N., Khalili, K., 1995. Transcriptional regulation of human JC poly-
omavirus promoters by cellular proteins YB-1 and Pur alpha in glial
cells. J. Virol. 69, 5843–5848.
Dalgliesh, A., Beverly, P., Clapham, P., et al., 1984. The CD4 antigen is an
essential component of the receptor for the AIDS. Nature 312, 763–
767.
Daniel, A.M., Swenson, J.J., Mayreddy, R.P., Khalili, K., Frisque, R.J.,
1996. Sequences within the early and late promoters of archetype JC
virus restrict viral DNA replication and infectivity. Virology 216 (1),
90–101.
Dubois, V., Dutronc, H., Lafon, M.-E., Poinsot, V., Pellegrin, J.-L., Rag-
naud, J.-M., Ferrer, A.-M., Fleury, H.J.A., 1997. Latency and reacti-
vation of JC Virus in peripheral blood of human immunodeficiency
virus type-1 infected patients. J. Clin. Microbiol. 35, 2288–2292.
Elsner, C., Dorries, K., 1992. Evidence of human polyomavirus BK and JC
infection in normal brain tissue. Virology 191, 72–80.
Feigenbaum, L., Hinrichs, S.H., Jay, G., 1992. JC virus and simian virus 40
enhancers and transforming proteins: role in determining tissue speci-
ficity and pathogenicity in transgenic mice. J. Virol. 66 (2), 1176–
1182.
Haun, G., Keppler, O.T., Bock, C.T., Herrmann, M., Zentgraf, H., Pawlita,
M., 1993. The cell surface receptor is a major determinant restricting
the host range of the B-lymphotropic papovavirus. J. Virol. 67, 7482–
7492.
Haywood, A.M., 1994. Virus receptors: binding, adhesion strengthening,
and changes in viral structure. J. Virol. 68, 1–5.
Hou, J., Major, E.O., 2000. Progressive multifocal leukoencephalopathy:
JC virus induced demyelination in the immune compromised host.
J. Neurovirol. 6 (Suppl 2), S98–S100.
Kenney, S., Natarajan, V., Strike, D., Khoury, G., Salzman, N.P., 1984. JC
virus enhancer-promoter active in human brain cells. Science 226
(4680), 1337–1339.
Kerr, D., Chang, C., Chen, N., Gallia, G., Raj, G., Schwartz, B., Khalili, K.,
1994. Transcription of a human neurotropic virus promoter in glial
cells: effect of YB-1 on expression of the JC virus late gene. J. Virol.
68, 7637–7643.
Komagome, R., Sawa, H., Suzuki, T., Suzuki, Y., Tanaka, S., Atwood,
W.J., Nagashima, K., 2002. Oligosaccharides as receptors for JC virus.
J. Virol. 76 (24), 12992–13000.
Lassak, A., Del Valle, L., Peruzzi, F., Wang, J.Y., Enam, S., Croul, S.,
Khalili, K., Reiss, K., 2002. Insulin receptor substrate 1 translocation to
the nucleus by the human JC virus T-antigen. J. Biol. Chem. 27, 27.
Lipton, H.L., 1991. Is JC Virus latent in the brain. Ann. Neurol. 29,
433–434.
Liu, C.K., Wei, G., Atwood, W.J., 1998. Infection of glial cells by the
human polyomavirus JC is mediated by an N-linked glycoprotein
containing terminal alpha 2-6 linked sialic acids. J. Virol. 72, 4643–
4649.
Liu, M., Kumar, K.U., Pater, M.M., Pater, A., 1997. Dual NF1-requiring
effect of human neurotropic JC virus composite pentanucleotide repeat
elements on early and late viral gene expression. Virology 227 (1),
7–12.
Major, E.O., Amemiya, K., Tornatore, C.S., Houff, S.A., Berger, J.R.,
1992. Pathogenesis and molecular biology of progressive multifocal
leukoencephalopathy, the JC virus-induced demyelinating disease of
the human brain. Clin. Microbiol. Rev. 5, 49–73.
Major, E.O., Miller, A.E., Mourrain, P., Traub, R.G., de Widt, E., Sever, J.,
1985. Establishment of a line of human fetal glial cells that supports JC
virus multiplication. Proc. Natl. Acad. Sci. USA 82, 1257–1261.
Mei, Y.F., Wadell, G., 1995. Molecular determinants of adenovirus tro-
pism. Curr. Top. Microbiol. Immunol. 199, 213–228.
Monaco, M.C., Sabath, B.F., Durham, L.C., Major, E.O., 2001. JC virus
multiplication in human hematopoietic progenitor cells requires the
NF-1 class D transcription factor. J. Virol. 75 (20), 9687–9695.
Monaco, M.G.C., Atwood, W.J., Gravell, M., Tornatore, C.S., Major, E.O.,
1996. JCV infection of hematopoetic progenitor cells, primary B lym-
phocytes, and tonsillar stromal cells: implication for viral latency.
J. Virol. 70, 7004–7012.
Mori, M., Kurata, H., Tajima, M., Shimada, H., 1991. JC virus detection by
in situ hybridization in brain tissue from elderly patients. Ann. Neurol.
29, 428–432.
Neuman, J., Morency, C., Russian, K., 1987. A novel rapid assay for
chloramphenicol acetyltransferase gene expression. Biotechniques. 5,
444–447.
Potash, M.J., Volsky, D.J., 1998. Viral interference in HIV-1 infected cells.
Rev. Med. Virol. 8 (4), 203–211.
108 G.V. Gee et al. / Virology 314 (2003) 101–109
Raj, G.V., Khalili, K., 1995. Transcriptional regulation: lessons from the
human neurotropic polyomavirus, JCV. Virology 213, 283–291.
Raj, G.V., Safak, M., MacDonald, G.H., Khalili, K., 1996. Transcriptional
regulation of human polyomavirus, JC: Evidence for a functional in-
teraction between Re1A (p65) and the Y-box binding protein, YB-1.
J. Virol. 70, 5944–5953.
Ranganathan, P.N., Khalili, K., 1993. The transcriptional enhancer ele-
ment, kappa B, regulates promoter activity of the human neurotropic
virus, JCV, in cells derived from the CNS. Nucleic Acids Res. 21,
1959–1964.
Ricciardiello, L., Laghi, L., Ramamirtham, P., Chang, C.L., Chang, D.K.,
Randolph, A.E., Boland, C.R., 2000. JC virus DNA sequences are
frequently present in the human upper and lower gastrointestinal tract.
Gastroenterology 119 (5), 1228–1235.
Sumner, C., Shinohara, T., Durham, L., Traub, R., Major, E., Amemiya,
K., 1996. Expression of multiple classes of the nuclear factor-1 family
in the developing human brain: differential expression of two classes of
NF-1 genes. J. Neurovirol. 2, 87–100.
Suzuki, S., Sawa, H., Komagome, R., Orba, Y., Yamada, M., Okada, Y.,
Ishida, Y., Nishihara, H., Tanaka, S., Nagashima, K., 2001. Broad
distribution of the JC virus receptor contrasts with a marked cellular
restriction of virus replication. Virology 286 (1), 100–112.
Sweet, T.M., Valle, L.D.K.K., 2002. Molecular biology and immunoregulation of
human neurotropic JC virus in CNS. J. Cell. Physiol. 191 (3), 249–256.
Tamura, T., Inoue, T., Nagata, K., Mikoshiba, K., 1988. Enhancer of
human polyoma JC virus contains nuclear factor-1 binding. Biochem.
Biophys. Res. Commun. 157, 419–425.
Telenti, A., Marshall, W., Aksamit, A., Smilack, J., Smith, T., 1992.
Detection of JC virus by polymerase chain reaction in cerebrospinal
fluid. Eur. J. Clin. Microbiol. Infect. Dis. 11, 253–254.
Tornatore, C., Amemiya, K., Atwood, W., Conant, K., Major, E.O., Berger,
J., 1994. JC Virus—current concepts and controversies in the molec-
ular virology and pathogenesis of progressive multifocal leukoenceph-
alopathy. Rev. Med. Virol. 4, 197–219.
Vacante, D.A., Traub, R., Major, E.O., 1989. Extension of JC virus host
range to monkey cells by insertion of a simian virus 40 enhancer into
the JC virus regulatory region. Virology 170, 353–361.
Vago, L., Cinque, P., Sala, E., Nebuloni, M., Caldarelli, R., Racca, R.,
Ferrante, P., Trabattoni, G., Costanzi, G., 1996. JCV-DNA and BKV-
DNA in the CNS tissue and CSF of AIDS patients and normal subjects.
Study of 41 cases and review of the literature. J. Aquir. Immune Defic.
Syndr. Hum. Retrovirology 12, 139–146.
VandeWoude, S., Hageman, C.A., O’Brien, S.J., Hoover, E.A., 2002.
Nonpathogenic lion and puma lentiviruses impart resistance to super-
infection by virulent feline immunodeficiency virus. J. Acquir. Immune
Defic. Syndr. 29 (1), 1–10.
Wei, G., Liu, C.K., Atwood, W.J., 2000. JC virus binds to primary human
glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T-
lymphocytes. J. Neurovirol. 6 (2), 127–136.
White III, F.A., Ishaq, M., Stoner, G.L., Frisque, R.J., 1992. JC Virus
DNA is present in many human brain samples from patients without
progressive multifocal leukoencephalopathy. J. Virol. 66, 5726 –
5734.
109G.V. Gee et al. / Virology 314 (2003) 101–109
